Related Experiment Video
Updated: Aug 20, 2025

Optical Coherence Tomography Based Biomechanical Fluid-Structure Interaction Analysis of Coronary Atherosclerosis Progression
Published on: January 15, 2022
Coronary plaque progression is greater in systemic lupus erythematosus than rheumatoid arthritis
Jeff Moore1,2, Suvasini Lakshmanan1, Venkat Sanjay Manubolu1
1Chronic Disease Clinical Research Center, The Lundquist Institute for Biomedical Innovation at the Harbor University of California Los Angeles Medical Center, Torrance.
Insights
Systemic lupus erythematosus (SLE) patients showed significantly greater progression of coronary plaque, including fibrous, noncalcified, and total plaque, compared to rheumatoid arthritis (RA) patients. This finding highlights increased cardiovascular risk in SLE requiring further investigation.
Area of Science:
- Cardiovascular Disease Research
- Rheumatology
- Immunology
Background:
- Systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) are linked to increased cardiovascular disease (CVD) incidence.
- Coronary atherosclerosis, especially noncalcified plaque, is a marker for CVD events.
- This study compares coronary plaque burden and progression in SLE and RA patients.
Purpose of the Study:
- To compare baseline coronary plaque burden and progression between SLE and RA patients using serial CCTA.
- To investigate the impact of SLE diagnosis on the rate of coronary plaque progression.
Main Methods:
- Prospective evaluation of 44 patients (22 SLE, 22 RA) with serial CCTA.
- Quantitative plaque assessment using semiautomated software.
- Linear regression to analyze the effect of SLE on plaque volume changes.
Main Results:
- No baseline differences in plaque types between SLE and RA patients.
- SLE patients exhibited significantly higher progression in fibrous, total noncalcified, and total plaque volumes compared to RA patients after risk factor adjustment.
- SLE patients had substantially greater increases in fibrous (80%), noncalcified (82%), and total plaque (85%) compared to RA patients.
Conclusions:
- Coronary plaque volume is similar at baseline in RA and SLE.
- Greater plaque progression in SLE patients may explain their elevated cardiovascular risk.
- Further research on screening and management strategies for CVD in high-risk SLE patients is essential.
Background:
Systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) are associated with a high incidence of cardiovascular disease. Coronary atherosclerosis, particularly total plaque and noncalcified plaque on coronary computed tomography angiography (CCTA) has been correlated with cardiovascular events. We compared baseline coronary plaque burden and progression by serial CCTA in SLE and RA patients.
Methods:
We prospectively evaluated 44 patients who underwent serial CCTA examinations to quantify coronary plaque progression, 22 SLE patients, and 22 age- and sex-matched RA patients. Semiautomated plaque software was used for quantitative plaque assessment. Linear regression examined the effect of SLE diagnosis (versus RA) on annualized change in natural log-transformed total normalized atheroma volume (ln-TAV norm ) for low-attenuation, fibrofatty, fibrous, total noncalcified, densely calcified, and total plaque.
Results:
No quantitative differences for any plaque types were observed at baseline between SLE and RA patients ( P = 0.330-0.990). After adjustment for baseline plaque and cardiovascular risk factors, the increase in ln-TAV norm was higher in SLE than RA patients for fibrous [Exp-β: 0.202 (0.398), P = 0.0003], total noncalcified [Exp-β: 0.179 (0.393), P = 0.0001], and total plaque volume [Exp-β: 0.154 (0.501), P = 0.0007], but not for low-attenuation, fibrofatty, or densely calcified plaque ( P = 0.103-0.489). Patients with SLE had 80% more fibrous, 82% more noncalcified, and 85% more total plaque increase than those with RA.
Conclusion:
Coronary plaque volume was similar in RA and SLE at baseline. Progression was greater in SLE, which may explain the greater cardiovascular risk in this disease. Further research to evaluate screening and management strategies for cardiovascular disease in these high-risk patients is warranted.
Related Concept Videos
Atherosclerosis I: Introduction
Coronary Artery Disease II: Pathophysiology
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
Rheumatic Heart Disease I: Introduction
Coronary Artery Disease I: Introduction

